Abiraterone-Induced Rhabdomyolysis in Prostate Cancer: A Report of Two Cases and Review of the Literature

Sanaz Ghafouri and Alexandra Drakaki

Department of Internal Medicine, University of California, USA

^*Correspondance to: Sanaz Ghafouri 

 PDF  Full Text Case Report | Open Access

Abstract:

Background: Abiraterone is a hormone targeted treatment that is used along with the standard androgen deprivation therapy for castration-resistant prostate cancers and has recently been proven to improve survival outcomes when used for castration-sensitive prostate cancers as well. However, to date, there is little literature on a fatal complication of this medication, which is rhabdomyolysis.Patient Description: We report a case series of two patients, a 72-year-old and an 80-year-old male, both with metastatic castration-resistant prostate cancers who developed rhabdomyolysis within a few weeks of starting Abiraterone. Both individuals showed significant recovery shortly after discontinuation of Abiraterone.Conclusion: This case highlights the importance of recognizing rhabdomyolysis early in patients started on Abiraterone, as this serious complication may be more common than previously suspected. This association becomes particularly important clinically now that there will be an increased frequency in the use of Abiraterone given recent studies showing its benefits when started early for patients with castration-sensitive prostate cancers as well.

Keywords:

Cite the Article:

Ghafouri S, Drakaki A. Abiraterone- Induced Rhabdomyolysis in Prostate Cancer: A Report of Two Cases and Review of the Literature. Ann Clin Case Rep. 2018; 3: 1533.